Viscosupplementation Market is expected to expand at a steady CAGR till 2023

Written by

Viscosupplementation Market Highlights:

The increasing patient preference to opt for minimally invasive procedures is anticipated to alter the development of the viscosupplementation market. The surge in the geriatric population is a major contributor towards the viscosupplementation market’s progress. The increased prevalence of ailments, such as obesity, hypertension, diabetes, renal failure, and cardiovascular diseases, is expected to create novel opportunities for expansion in the approaching period.

The surge in knee osteoarthritis knee cases is influencing the progress of the viscosupplementation market. Reports that review the healthcare industry has been offered by Market Research Future, which generates reports on industry verticals that evaluate the market development and opportunities. The market is capitalizing a CAGR of 8.96% to reach incomes worth USD 5,243.19 million by the end of the forecast.

Segmental Analysis:

The analysis of the segments in the viscosupplementation market carried out on the basis of hyaluronic acid type, application, procedure type, region, and end-user. Based on the hyaluronic acid type, the viscosupplementation market is segmented into standard hyaluronic acid and stabilized hyaluronic acid. Based on the procedure type, the viscosupplementation market is segmented into three-injection procedure, single-injection procedure, and five-injection procedure. Based on application, the viscosupplementation market is segmented into hip osteoarthritis and knee arthritis. The knee arthritis segment was accountable for the chief market share trailed by hip osteoarthritis. On the basis of region, the viscosupplementation market is segmented into the Asia Pacific, the Americas, Europe, and the Middle East Afric

Competitive Analysis:

The industry cost make-up is also likely to modify with time. The market conditions are extremely dependent on the factors that are influencing the prospects and the challenges that are prevailing in the market. The players in the market are making certain that the product and services being offered in the market are supporting the preferences of their user base favorably.

The innovative trends emerging in the market are expected to set the foundation for vigorous development in the forthcoming period. The market size is also anticipated to increase significantly in the approaching years. Also, the development of technology has increased momentum, guiding to improved market growth. The incidence of popular products and brands is determining the expansion of the market to a significant extent.

The strategic success features are also constructively impacting the evolution of the market. The reinforcement of the distribution channels in the market is presumed to augment the saturation of the products. In the approaching years, market viability will increasingly improve as modernization, and product advances encourage positive changes.

The well-known contenders in the viscosupplementation market are Allergan, Regen Lab SA, Zimmer Biomet, Smith Nephew Plc, Anika Therapeutics Inc., Fidia Farmaceutici S.P.A., Hoffmann-La Roche, Ferring B.V., Bioventus, and others.


Detailed Regional Analysis:

The evaluation of the regions in the viscosupplementation market includes the Asia Pacific, the Americas, Europe, and the Middle East Africa. The Americas region is responsible for the chief market share in 2017 and is expected to develop at the highest CAGR through the forecast period due to variation in the patient presence. The other factors such as knee replacement surgeries to minimally invasive viscosupplementation techniques for the treatment of knee osteoarthritis, the incidence of chief market participants and the presence of complex healthcare infrastructure, and a swift surge in demand for viscosupplementation products. The Asia Pacific region is shadowed by the European region, which controls the second chief market share, and it is likely to reach USD 447.24 million by 2023 at a CAGR of 10.48%. The UK was responsible for the maximum market stake in the European region and is anticipated to remain central throughout the forecast period due to the growing geriatric population in this region. On the other hand, the intensifying awareness about single-injection treatment, and intensifying preference for minimally invasive surgeries in Japan, China, India, and Australia are likely to back the market growth of the Asia Pacific region through the forecast period from 2018 to 2023.


Article Categories:

Leave a Reply

Your email address will not be published. Required fields are marked *